Global Blood Platelets Market is segmented By Application (Platelet Function Disorders, Hemophilia, Thrombocytopenia, Perioperative Indications), By End-user (Hospitals, Ambulatory Surgical Centers, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Blood Platelets Market Overview
The global blood platelets market is estimated to reach at a high CAGR during the forecast period 2022-2029.
Platelets are the components of blood essential for the clotting of blood, also known as thrombocytes. Bleeding occurs in the case of low platelet count. Platelets stop the bleeding mainly by clumping and forming plugs in blood vessels that have been injured.
Blood Platelets Market Overview Scope
|
Metrics |
Details |
|
CAGR |
High |
|
Size Available for Years |
2022-2031 |
|
Forecast Period |
2024-2031 |
|
Data Availability |
Value (US$) |
|
Segments Covered |
Application, End-User and Region |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America and Middle East & Africa |
|
Fastest Growing Region |
Asia-Pacific |
|
Largest Region |
North America |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
To Know More: Download Sample
Blood Platelets Market Dynamics
The blood platelets market growth is driven by the rising prevalence of chronic blood-related disorders and the increasing number of surgical procedures, rise in awareness regarding blood donations and platelets transfusions and favorable reimbursement policies in developed countries
The rising prevalence of chronic blood-related disorders is expected to drive growth in the forecast period.
With the increasing prevalence of chronic blood-related disorders such as myelofibrosis, hemophilia and thrombocytopenia, there is an increased demand for blood platelets. According to the 2019 Annual Global Survey by the World Federation of Hemophilia, 324,648 people were identified with bleeding disorders out of 5.5 billion people worldwide. Moreover, liver disorder patients are more often at risk of platelet reduction. For example, as per a 2021 article by the Centers for Disease Control and Prevention (CDC), 4.5 million adults were diagnosed with liver disorders in the United States in 2018. In addition, as per a 2021 article by the World Gastroenterology Organization (WHO), liver cirrhosis was one of the leading causes of death in 2020. Thus, the growing prevalence of these disorders is projected to boost the demand for blood platelets treatment via hematopoietic stem cell transfer or transfusion methods.
The increasing number of surgical procedures is expected to drive growth in the forecast period.
The increasing number of surgical procedures across the globe is also contributing to the increasing demand for blood platelets. An increase in orthopedic and cardiac surgeries is contributing to the rising demand for blood platelets in hospitals. In addition, an increase in organ transplantations has boosted the demand for blood platelets. For instance, as per the Global Observatory on Donation and Transplantation data, 153,863 organs were transplanted annually in 2019, which was a 4.8% increase from 2018. In addition, an increase in the number of trauma surgeries by impact forces such as accidents, falls, sports and crush injuries are projected to boost the demand for blood platelets in the coming years. For instance, per the 2021 statistics by the World Health Organization (WHO), 20-50 million people suffer from non-fatal road injuries each year. Such a huge number indicates the rising need for blood platelets in these populations. Thus, all the factors mentioned above are currently augmenting the growth of the blood platelets market.
High risk of transmissions of infections are likely to hamper market growth.
Blood transfusions carry significant risks. Among these, the transmission of infectious organisms (e.g., viral or bacterial) remains one of the most feared complications. Hepatitis B was once the most serious transfusion risk. However, unnecessary transfusion should be avoided further to reduce the risk for infection and other complications.
Blood Platelets Market Industry Analysis
COVID-19 Impact Analysis On Blood Platelets Market
The COVID-19 outbreak is an unprecedented health concern that has impacted the global blood platelets market. The onset of the COVID-19 pandemic has led several blood donation organizations to introduce safety guidelines about blood donation. For example, in July 2020, World Health Organization (WHO) introduced interim guidance on maintaining a safe and adequate blood supply during the COVID-19 pandemic. Moreover, countries worldwide are facing a shortage of blood donors. Furthermore, as per an article by The Lancet Hematology, the percentage of donors fell by 30% in 2020 at the Canadian Blood Services. Hence, several organizations such as the American Association of Blood Banks (AABB), American Blood Centers (ABC), and the American Red Cross issued a joint statement in May 2020, urging the public to donate blood during the pandemic. Such initiatives for blood donation can meet the demand for blood platelets by healthcare facilities in the pandemic.
Blood Platelets Market Segment Analysis
The platelet function disorders segment is expected to hold the largest share in this market segment.
Platelet function disorders show significant growth due to the increasing prevalence of cancer cases. Chronic myelogenous leukemia and multiple myeloma cancers lead to acquired platelet function disorders in some cancer patients. Therefore, cancer patients must undergo platelet transfusions frequently. Moreover, as per the American Cancer Society estimates, about 34,920 people will be diagnosed with multiple myeloma in 2021 in the United States. In addition, as per the 2021 statistics by Cancer Research UK, incidence rates for myeloma are projected to increase by 11% in the United Kingdom between 2014 and 2035. Such numbers indicate the rising demand for platelet transfusion in the treatment of cancer patients.
Furthermore, chronic platelet function disorders also contribute to the increasing demand for platelet transfusion. Thus, the administration of platelets in such patients is frequently performed to mitigate complications, including RBC requirements, surgical blood loss, and reoperation for bleeding. Thus, given the abovementioned factors, the segment is anticipated to grow significantly over the forecast period.
The hospital segment is expected to hold the largest share in this market segment.
The hospital segment held the largest share in the blood platelets market due to the availability of skilled technicians, improved healthcare infrastructure, and high accessibility and affordability of hospitals in conducting testing procedures. An increase in the number of admissions of patients in hospitals suffering from cancer disorders, hemophilia and other severe platelet disorders contributes to the blood platelet market growth.
Additionally, higher availability of blood components in hospitals results in increased utilization of blood platelets, resulting in increased adoption. An increase in the number of surgeries and severe injuries requiring blood transfusions further impels the demand for blood platelets in hospitals. Furthermore, fair reimbursement policies for blood transfusion procedures result in an increased demand for blood platelets by the hospitals.
Blood Platelets Market Geographical Analysis
North America region holds the largest market share of the global blood platelets market.
In North America, United States held a major share of the blood platelets market and is expected to show a similar trend over the forecast period, without significant fluctuations. This is majorly attributed to the factors such as the presence of several organizations engaged in the distribution of blood components. Furthermore, these organizations in the region are engaged in increasing awareness in the region regarding the importance of blood donation, increasing the number of blood donors in the region. For instance, according to the 2020 statistics by the Centers for Disease Control and Prevention (CDC), presently, there are more than 13.2 million blood donors in the United States. Moreover, the number of platelet transfusions in the region has boosted the demand for blood platelets. For example, as per the 2021 statistics by The American National Red Cross, approximately 21 million blood components are transfused each year in the United States. Thus, given the factors mentioned above, the blood platelets market is anticipated to grow significantly over the forecast period in North America.
Blood Platelets Market Competitive Landscape
The global blood platelets market is moderately competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include The American National Red Cross, America’s Blood Centers, American Association of Blood Banks (AABB), Blood Centers of America, Brazilian Red Cross, Canadian Blood Services, European Blood Alliance (EBA), OneBlood, Cellphire, Inc and PlateletBio, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, In May 2021, Canadian Blood Services entered a contract with Cercus Corporation for the INTERCEPT Blood System for platelets.
Blood Platelets Market Key Companies to Watch
Cellphire, Inc
Overview: Cellphire Therapeutics is a biotechnology company focused on developing platelet-based products to save lives. Its lead product, Thrombosomes, is a platelet-based freeze-dried hemostatic. Headquartered in Rockville, Maryland, our 32,000-square-foot facility includes 9,500 square feet of lab and clean-room manufacturing space. Cellphire is collaborating with U.S. government research agencies, universities, blood centers, and industry partners to advance the development of novel platelet-based therapeutics for a range of applications from the treatment of acute and chronic bleeding to drug delivery and regenerative medicine.
Product Portfolio: The Company’s portfolio comprised of include hemostasis, targeted drug delivery, and regenerative medicine. They also support animal health through their veterinary subsidiary BodeVet.
Key developments: In May 2021, Cellphire, Inc. announced that their first patient has been dosed in Phase 2 dose-ranging study of a platelet-based freeze-dried hemostatic agent, in bleeding patients with thrombocytopenia called Thrombosomes. This study will evaluate the safety and efficacy of infusing multiple dose levels of Thrombosomes versus standard liquid stored platelets.
The global blood platelets market report would provide an access to an approx. 53 market data table, 43 figures and 200 pages.
